MedTrace Logo

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00053391 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2015-05-12

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV melanoma.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

recombinant CD40-ligand

BIOLOGICAL

therapeutic autologous dendritic cells

Sponsors & Collaborators

  • University Hospital Erlangen

    lead OTHER

Principal Investigators

  • Gerold Schuler · Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2005-06-30
Completion
2007-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00053391 on ClinicalTrials.gov